Thoratec downgraded to Market Perform from Outperform at Northland Securities

theflyonthewall.com

Northland downgraded Thoratec following the CMS's announcement to initiate a National Coverage Decision analysis for VAD therapy. The firm believes there is now significant uncertainty regarding VADs and margins. Price target is $35.

Rates

View Comments